CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
2016-2017 Influenza Vaccinebiological
Likely dose
2016-2017 Influenza Vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02876159
NCT02876159Phase 4Completed
CompareCT.gov

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

Emory University·interventional·Posted Aug 23, 2016·Updated Dec 12, 2018

In Brief

A Phase 4 clinical trial evaluating 2016-2017 Influenza Vaccine for Influenza. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This is a prospective pilot study designed to suggest differences in the immunologic response to the seasonal influenza vaccine in people with regular vaccination history compared to those vaccinated less regularly. Participants will receive one dose of the Food and Drug Administration (FDA) approved 2016-2017 seasonal influenza vaccine. Immune system data will be collected at standard time points. The duration of the study for each participant will be approximately 1 month.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 23, 2016
Enrollment StartJul 1, 2016
Primary CompletionOct 18, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.9 years ago

Interventions

2016-2017 Influenza Vaccinebiological

Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.